{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:35:08Z","timestamp":1789943708086,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":741,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1093\/annonc\/mdx536","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T11:08:29Z","timestamp":1505992109000},"page":"2994-2999","source":"Crossref","is-referenced-by-count":56,"title":["Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)"],"prefix":"10.1016","volume":"28","author":[{"given":"J.","family":"Martin-Broto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Garcia del Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carnero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Marcilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Martinez-Trufero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Diaz-Beveridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Taron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lopez-Pousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx536_bb0010","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0015","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/pbc.25963","article-title":"Prevalence of metastasis at diagnosis of osteosarcoma: an international comparison","volume":"63","author":"Marko","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0020","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.2003.03.141","article-title":"Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival","volume":"21","author":"Ferrari","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx536_bb0025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40272-014-0095-z","article-title":"The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma","volume":"16","author":"Xiao","year":"2014","journal-title":"Paediatr Drugs"},{"key":"10.1093\/annonc\/mdx536_bb0030","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1200\/JCO.1997.15.6.2378","article-title":"High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies\u2014dose\u2013response and schedule dependence","volume":"15","author":"Patel","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx536_bb0035","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cncr.24368","article-title":"Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients","volume":"115","author":"Berger","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cncr.23586","article-title":"Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma","volume":"113","author":"Navid","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0045","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ejca.2011.12.015","article-title":"A phase II trial of second-line pemetrexed in adults with advanced\/metastatic osteosarcoma","volume":"48","author":"Duffaud","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0050","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pbc.24868","article-title":"High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG\/SSG II study","volume":"61","author":"Boye","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","article-title":"Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial","volume":"16","author":"Grignani","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx536_bb0060","first-page":"55","article-title":"The current and future therapies for human osteosarcoma","volume":"9","author":"Lamplot","year":"2013","journal-title":"Curr Cancer Ther Rev"},{"key":"10.1093\/annonc\/mdx536_bb0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-3-319-04843-7_11","article-title":"Participation of the Fas\/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases","volume":"804","author":"Huang","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"10.1093\/annonc\/mdx536_bb0070","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s12032-009-9365-y","article-title":"mTOR\/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis","volume":"27","author":"Zhou","year":"2010","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdx536_bb0075","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.2011.35.6329","article-title":"Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas","volume":"30","author":"Chawla","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx536_bb0080","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ejca.2012.03.022","article-title":"Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma","volume":"48","author":"Schuetze","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0085","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/bjc.2014.370","article-title":"Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours","volume":"111","author":"Martin-Liberal","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0090","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ejca.2010.11.036","article-title":"Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials","volume":"47","author":"Gelderblom","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0095","doi-asserted-by":"crossref","first-page":"321.","DOI":"10.1634\/theoncologist.2010-0265","article-title":"Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003","volume":"17","author":"Fox","year":"2012","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdx536_bb0100","doi-asserted-by":"crossref","first-page":"280.","DOI":"10.1186\/s12885-016-2312-3","article-title":"Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone","volume":"16","author":"Palmerini","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jjco\/hys030","article-title":"Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients","volume":"42","author":"Qi","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdx536_bb0110","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.11563","article-title":"Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma","volume":"98","author":"Laverdiere","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx536_bb0115","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1158\/0008-5472.CAN-04-3135","article-title":"Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma","volume":"65","author":"Wan","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdx536_bb0120","first-page":"6725","article-title":"Prognostic value of p53 alterations in human osteosarcoma: a meta analysis","volume":"7","author":"Yao","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1093\/annonc\/mdx536_bb0125","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdr151","article-title":"A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study","volume":"23","author":"Grignani","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx536_bb0130","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-03-0156","article-title":"Ribonucleotide reductase messenger RNA expression and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients","volume":"10","author":"Rosell","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx536_bb0135","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(10)70244-8","article-title":"The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer","volume":"12","author":"Jordheim","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx536_bb0140","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.18632\/oncotarget.3498","article-title":"Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets","volume":"6","author":"Movva","year":"2015","journal-title":"Oncotarget"},{"key":"10.1093\/annonc\/mdx536_bb0145","doi-asserted-by":"crossref","first-page":"503","DOI":"10.18632\/genesandcancer.91","article-title":"MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1\/2 phosphorylation","volume":"6","author":"Baranski","year":"2015","journal-title":"Genes Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419353980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419353980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/12\/2994\/22295569\/mdx536.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:11:25Z","timestamp":1624695085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419353980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0923753419353980"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx536","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}